Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3CNS 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Sarcoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 8Specimen Handling 5Magnetic Resonance Spectroscopy 5pembrolizumab 3Everolimus 3cabozantinib 2X-Rays 2repotrectinib 1peposertib 1pazopanib 1olaparib 1lenvatinib 1fludarabine 1entrectinib 1belinostat 1aldesleukin 1Watchful Waiting 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Sunitinib 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1Photons 1Phantoms, Imaging 1PT-100 dipeptide 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
entrectinib × NET × 30 days × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡